SCNI

JERUSALEM, April 6, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI); ("Scinai" or the "Company"), a biopharmaceutical company developing inflammation and immunology therapeutics and operating a growing CDMO business, today announced the completion of a strategic corporate reorganization establishing a dedicated CDMO platform alongside a streamlined R&D organization. Building on its previously announced acquisition of Recipharm Israel Ltd. and related commercial collaboration with Recipharm, this reorganization represents a structural transformation of the Company's operating model, designed to enhance capital efficiency, improve operational focus and position each business

JERUSALEM, April 1, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI); ("Scinai" or the "Company"), a biopharmaceutical company operating a dual R&D and CDMO business model designed to combine therapeutic innovation with revenue-generating drug development and manufacturing services, today reported financial results for the year ended December 31, 2025. Corporate and Financial HighlightsCDMO revenues doubled year-over-year to $1.3 million, reflecting continued commercial traction and execution of development and manufacturing programsExpanded CDMO platform post year-end through the acquisition of Recipharm Israel and entry into a strategic commercial collaboration with Reciph

20-F - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)

3 - Scinai Immunotherapeutics Ltd. (0001611747) (Issuer)

6-K - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)

6-K - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)

JERUSALEM, March 19, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI), a biopharmaceutical company advancing a pipeline of innovative inflammation and immunology therapeutics, and the owner of Scinai Biopharma Services Ltd., a rapidly expanding contract development and manufacturing organization (CDMO) serving biotechnology and pharmaceutical companies, today announced its participation in BIO-Europe Spring® 2026, taking place March 23–25 in Lisbon, Portugal. This will be Scinai's first major international conference following its recent acquisition of Recipharm Israel and strategic collaboration with Recipharm, marking a significant expansion of its development and manufact

3 - Scinai Immunotherapeutics Ltd. (0001611747) (Issuer)

3 - Scinai Immunotherapeutics Ltd. (0001611747) (Issuer)

3 - Scinai Immunotherapeutics Ltd. (0001611747) (Issuer)

3 - Scinai Immunotherapeutics Ltd. (0001611747) (Issuer)

3 - Scinai Immunotherapeutics Ltd. (0001611747) (Issuer)

3 - Scinai Immunotherapeutics Ltd. (0001611747) (Issuer)

3 - Scinai Immunotherapeutics Ltd. (0001611747) (Issuer)

JERUSALEM, March 16, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) ("Scinai" or the "Company"), today announced that it received a written notification from the Nasdaq Listing Qualifications Department on March 12, 2026 indicating that the Company is not in compliance with the Nasdaq Capital Market's minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2), because the closing bid price of the American Depositary Shares ("ADSs") was below $1.00 per share for 30 consecutive business days. The notification has no immediate effect on the listing or trading of the ADSs on the Nasdaq Capital Market.In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has

JERUSALEM, March 2, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI);("Scinai" or the "Company"), today announced the execution of a Second Amendment to its Binding Option Agreement for the acquisition of PinCell S.r.l., and the submission of a revised application under the European Funds for the Modern Economy (FENG) SMART Path program. The Company's revised application seeks €12 million in non-dilutive, non-repayable funding to support a €15 million integrated R&D program for PC111 a fully human monoclonal antibody targeting soluble Fas Ligand (sFasL) for the treatment of pemphigus vulgaris (PV) and Stevens–Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN), representin

6-K - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)

JERUSALEM, Feb. 25, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI);("Scinai", or the "Company"), today announced that, following an additional review by the Israel Innovation Authority (IIA), its project to advance a robotic aseptic fill & finish platform has been approved for expanded support. With this update, Scinai is now utilizing the full approved grant budget for the program, totaling NIS 5 million over two years, approximately 66% of which is non-dilutive funding.The program supports the acquisition and validation of a fully automated, versatile robotic-arm aseptic fill & finish system designed to align with EU GMP Annex 1 standards. Validation of the system is tar

6-K - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)

JERUSALEM, Feb. 17, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) ("Scinai", or the "Company"), a biopharmaceutical company developing inflammation and immunology (I&I) therapeutics and operating a growing CDMO business, today announced that it has acquired 100% of the shares of Recipharm Israel Ltd., which operates Recipharm's site in Yavne, Israel, and entered into a long-term strategic commercial collaboration with Recipharm. The transactions significantly expand Scinai's manufacturing footprint, capabilities, and commercial positioning, strengthening its

JERUSALEM, Jan. 7, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI); ("Scinai", or the "Company"), a biopharmaceutical company developing inflammation and immunology (I&I) therapeutics and operating a growing boutique CDMO business unit, today announced that its Chief Executive Officer, Amir Reichman, will co-lead a roundtable discussion organized by the Manufacturers Association of Israel during HealthIL Week 2026. The roundtable, titled "Biopharma Manufacturing in Israel: Capabilities, Gaps, and Scale," will take place on January 19, 2026 at Expo Tel Aviv. The session is a Manufacturers Association–led roundtable and will be jointly led by Mr.  Reichman together with seni

6-K - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)

6-K - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)

JERUSALEM, Dec. 2, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) ("Scinai", or the "Company"), a biopharmaceutical company developing innovative inflammation and immunology (I&I) therapeutics and operating a growing boutique CDMO business unit, today reported its financial results and corporate highlights for the nine months ended September 30, 2025. First Nine Months 2025 Financial Summary Revenues for the nine months ended September 30, 2025 were $1,049 thousand, compared to $452 thousand for the nine months ended September 30, 2024. The increase reflects continued expansion of Scinai Bioservices, including contributions from the Company's U.S. subsidiary.R&D expenses

6-K - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)